Lumos Diagnostics HoldingsASX:LDX 31 Days Payable is 220.00 as of Dec. 2025, which is 191% above its 10-year median of 75.71. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 84.28% on this metric.
The historical rank and industry rank for Lumos Diagnostics Holdings's Days Payable or its related term are showing as below:
ASX:LDX'
s Days Payable Range Over the Past 10 Years
Min: 73.84 Med: 75.71 Max: 198.77
Current: 198.77
During the past 4 years, Lumos Diagnostics Holdings's highest Days Payable was 198.77. The lowest was 73.84. And the median was 75.71.
ASX:LDX's Days Payable is ranked better than 84.28% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs ASX:LDX: 198.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Days Payable falls into.
Lumos Diagnostics Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a Days Payable of 220.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumos Diagnostics Holdings and its competitors. This is 191% above median its historical median of 75.71. Over the past decade, Lumos Diagnostics Holdings' Days Payable has ranged from 73.84 to 198.77. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #125 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 15.7%.
Is Lumos Diagnostics Holdings' Days Payable too high?
Lumos Diagnostics Holdings' current Days Payable of 220.00 is 191% above median its 10-year median of 75.71. Over the past 10 years, this metric has ranged from a low of 73.84 to a high of 198.77. The Medical Devices & Instruments industry median Days Payable is 68.07. Lumos Diagnostics Holdings' value of 220.00 is 223.2% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #125 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #125 out of 795 companies for Days Payable. This places Lumos Diagnostics Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Lumos Diagnostics Holdings' value of 220.00 is 223.2% above this benchmark. Historically, Lumos Diagnostics Holdings' own Days Payable has ranged from 73.84 to 198.77 over the past decade. While the company's 10-year median is 75.71 vs. the industry median of 68.07, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Days Payable of 220.00 is 223.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Days Payable is 220.00, which is 191% above median its own 10-year median of 75.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current Days Payable is 220.00, which is 191% above median its 10-year median of 75.71 and 223.2% above the Medical Devices & Instruments industry median of 68.07. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Days Payable is 220.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
Days Payable: 220.00 (191% above median its 10-year median of 75.71)
GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
Industry Position: 223.2% above the Medical Devices & Instruments median (#125 of 795)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score
Get the complete analysis for ASX:LDX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
